Buy this Article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MA, RN

Abstract

* The Food and Drug Administration (FDA) has determined that drugs containing entacapone, used in the management of Parkinson's disease symptoms, does not increase the risk of cardiovascular events.

 

* This announcement reverses an older FDA Drug Safety Communication in which the agency expressed concerns over possible cardiovascular events associated with use of the drug.